Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (111-120 of 206) with videos related to

Pageof 21
Sort By:
The Journal of Experimental Medicine|February 17, 2010
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsSergio A Quezada, Tyler R Simpson, Karl S Peggs, et al.
Cancer|February 10, 2010
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalGeoffrey Y Ku, Jianda Yuan, David B Page, et al.
Cancer Research|August 5, 2008
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stageR Houston Thompson, Xingxing Zang, Christine M Lohse, et al.
Cell|August 15, 2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeSpencer C Wei, Jacob H Levine, Alexandria P Cogdill, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2019
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapiesSpencer C Wei, Nana-Ama A S Anang, Roshan Sharma, et al.
Annals of the New York Academy of Sciences|June 19, 2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaJedd D Wolchok, F Stephen Hodi, Jeffrey S Weber, et al.
Cancer Immunology, Immunotherapy : CII|April 6, 2011
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three casesJianda Yuan, Brian Ginsberg, David Page, et al.
Science (New York, N.Y.)|March 9, 2013
Aire-dependent thymic development of tumor-associated regulatory T cellsSven Malchow, Daniel S Leventhal, Saki Nishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational researchMartin A Cheever, James P Allison, Andrea S Ferris, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2010
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang, Peggy S Sullivan, Robert A Soslow, et al.
Pageof 21

Showing results (111-120 of 206) with videos related to

Sort By:
Pageof 21
The Journal of Experimental Medicine|February 17, 2010
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsSergio A Quezada, Tyler R Simpson, Karl S Peggs, et al.
Cancer|February 10, 2010
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalGeoffrey Y Ku, Jianda Yuan, David B Page, et al.
Cancer Research|August 5, 2008
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stageR Houston Thompson, Xingxing Zang, Christine M Lohse, et al.
Cell|August 15, 2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeSpencer C Wei, Jacob H Levine, Alexandria P Cogdill, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2019
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapiesSpencer C Wei, Nana-Ama A S Anang, Roshan Sharma, et al.
Annals of the New York Academy of Sciences|June 19, 2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaJedd D Wolchok, F Stephen Hodi, Jeffrey S Weber, et al.
Cancer Immunology, Immunotherapy : CII|April 6, 2011
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three casesJianda Yuan, Brian Ginsberg, David Page, et al.
Science (New York, N.Y.)|March 9, 2013
Aire-dependent thymic development of tumor-associated regulatory T cellsSven Malchow, Daniel S Leventhal, Saki Nishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational researchMartin A Cheever, James P Allison, Andrea S Ferris, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2010
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang, Peggy S Sullivan, Robert A Soslow, et al.
Pageof 21